Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
A Phase 1, Open-label Study to Evaluate the Safety and to Characterize the Pharmacokinetics of a Fixed-Dose Combination Formulation of Ceftibuten-Ledaborbactam Etzadroxil
Sponsor: Basilea Pharmaceutica
A PHASE1 clinical study on Drug-Drug Interaction (DDI) and FDC, this trial is actively recruiting participants. The trial is conducted by Basilea Pharmaceutica and has accumulated 8 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Apr 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Basilea Pharmaceutica
- Biomedical Advanced Research and Development Authority
For direct contact, visit the study record on ClinicalTrials.gov .